LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee - Candlesense
LSB Mergers

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for...

Related Questions

What are the key terms and valuation of the revised preliminary non‑binding acquisition proposal? When will the special committee be formed and what is the expected timeline for due diligence and shareholder approval? How is the proposed acquisition likely to affect the capital structure, dilution risk, and earnings outlook for existing shareholders?
Find similar articles on Candlesense prnewswire